Lumizyme (alglucosidase alfa) — Medical Benefit Medication Utilization Policy
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical benefit coverage criteria, authorization, quantity limits, and coding for Lumizyme (alglucosidase alfa) for treatment of Pompe disease for Community-Care members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lumizyme (alglucosidase alfa)
Initial Therapy — Infantile-onset Pompe disease
Covered when ALL of the following are met for infantile-onset Pompe disease:
Initial Therapy — Late-onset Pompe disease
Covered when ALL of the following are met for late-onset Pompe disease:
Continuation Therapy
Covered when ALL of the following are met for continuation:
For initial approval in infantile-onset Pompe disease, coverage requires a confirmed clinical diagnosis by either genetic sequencing or an acid alpha-glucosidase enzyme assay. Additionally, the prescription must come from a medical geneticist or neuromuscular specialist. These requirements ensure diagnostic certainty and specialist oversight prior to authorizing enzyme replacement therapy with alglucosidase alfa.
For late-onset Pompe disease, initial coverage similarly requires diagnostic confirmation by genetic sequencing or an acid alpha-glucosidase enzyme assay, and the drug must be prescribed by a medical geneticist or neuromuscular specialist. In addition, the patient must be symptomatic or have objective signs of Pompe disease to meet initial approval criteria.
Initial Therapy
Initial therapy
Covered when ALL of the following are met:
Continuation Therapy
Continuation therapy
Covered when ALL of the following are met:
Coding and Dosing
| J0221 | Injection, alglucosidase alfa, (Lumizyme), 10 mg |
Provider Actions and Requirements
Prior Authorization Required
Prior authorization is required for alglucosidase alfa (Lumizyme). When criteria are met, authorization will specify dosing of 20 mg/kg every 2 weeks. A current patient weight must be provided with the request. Authorizations, if approved, will be issued for up to one year.
- Required dosing when approved: 20 mg/kg every 2 weeks
- Weight required for approval: provide current patient weight with request
- Authorization period: up to 1 year (subject to benefit changes)
Provider Action — Submit Complete Request
Submit prior authorization requests and supporting documentation to Community-Care per payer procedures. Ensure the prescriber specialty and required documentation (see documentation callout) are included to avoid processing delays.
- Include prescriber specialty on the request (medical geneticist or neuromuscular specialist preferred)
- Provide member weight and proposed dosing schedule
- Attach clinical documentation confirming diagnosis and baseline/ongoing monitoring
Required Documentation
Required documentation must be submitted with the prior authorization request to establish medical necessity and support approval.
- Diagnostic confirmation of Pompe disease via genetic sequencing or acid alpha-glucosidase enzyme assay
- Prescriber specialty: medical geneticist or neuromuscular specialist (document specialty)
- For late-onset disease: documentation of symptoms or objective signs of Pompe disease
- Evidence of clinical benefit for continuation requests and documentation of ongoing monitoring
- Current member weight (for dosing/quantity calculation)
Triggers for Possible Denial
Requests may be denied or delayed if required information is missing or criteria are not met. Review these common triggers to reduce risk of denial.
- Missing diagnostic confirmation (no genetic testing or enzyme assay provided)
- Prescriber specialty not documented or prescriber outside recommended specialties
- No current patient weight provided
- For late-onset Pompe disease: absence of documented symptoms or objective signs when required
- Lack of documentation demonstrating benefit for continuation requests
Site of Care
Site of care
No site-of-care restrictions or special setting requirements are specified in the policy.
Quantity Limits and Dosing Calculations
Definitions
Background
Pompe disease is an inherited deficiency of acid alpha-glucosidase that presents as either infantile-onset or late-onset disease. Treatment is with enzyme replacement therapy using alglucosidase alfa (Lumizyme). Per policy, diagnostic confirmation by genetic sequencing or an acid alpha-glucosidase enzyme assay is required for initiation, and prescribers must be a medical geneticist or neuromuscular specialist. When approved, dosing is authorized at 20 mg/kg every 2 weeks and a member weight must be provided to calculate quantities; approvals are issued for one year when criteria are met.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.